Nektar Therapeutics has been granted a patent for a mixed-acid salt of a water-soluble polymer-drug conjugate, offering improved stability and resistance to degradation. The patent also covers a method for preparing a highly pure reactive multi-armed polyethylene glycol reagent for pharmaceutical conjugates. GlobalData’s report on Nektar Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Nektar Therapeutics - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Nektar Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Nektar Therapeutics's grant share as of January 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.

Mixed-acid salt of water-soluble polymer-drug conjugate

Source: United States Patent and Trademark Office (USPTO). Credit: Nektar Therapeutics

A recently granted patent (Publication Number: US11834553B2) discloses a method for preparing a highly pure reactive multi-armed polyethylene glycol reagent suitable for use in pharmaceutical conjugates. The method involves providing an isolated alkoxylatable oligomer with a specific weight-average molecular weight range and ensuring uniformity in the values of n during the process. The use of aprotic, substantially anhydrous organic solvents like toluene and specific strong bases such as metallic potassium or sodium hydroxide is integral to the method.

Furthermore, the method includes an alkoxylating step carried out at a specific temperature range to achieve the desired weight-average molecular weight for the polymeric product. The resulting reactive multi-armed polyethylene glycol reagent contains various reactive groups like carboxylic acid and N-hydroxysuccinimidyl ester, making it suitable for conjugation with biologically active agents. The patent also emphasizes the importance of maintaining high purity levels of the alkoxylated polymeric product for optimal results, with a purity requirement of over 97 weight percent. Overall, the patented method offers a systematic approach to producing a high-quality reactive polyethylene glycol reagent for pharmaceutical applications, ensuring consistency and purity throughout the process.

To know more about GlobalData’s detailed insights on Nektar Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies